1 **Title: Diversity in antibody titer at an average of 87 days after the second dose of**
2 **BNT162b2 mRNA coronavirus disease 2019 vaccine: data from a predominantly**
3 **elderly population in a practice in Tokyo**

4

5 **Short title: Antibody titer after second BNT162b2 mRNA COVID-2019 vaccine**
6 **among elderly**

7

8 Yasuko Fuse-Nagase, MD, PhD.^{1,2}

9 Mitsuo Nagase, MD, PhD.¹

10 1. Nagase Clinic

11 Tokumaru, Itabashi, Tokyo, Japan

12 2. University Health Center, Ibaraki University

13 Bunkyo, Mito, Ibaraki, Japan

14

15 Corresponding author: Yasuko Fuse-Nagase

16 E-mail: yasuko.fuse.uhc@vc.ibaraki.ac.jp

17

18

19 **Abstract**

20 It is very important for the elderly, who tend to have serious COVID-19 infection and
 21 high mortality rates, to maintain sufficient immunity. We reviewed the medical charts of
 22 predominantly elderly population to obtain the data on serum anti-SARS-CoV-2S
 23 antibody titer after complete vaccination with the BNT162b2 mRNA vaccine (two
 24 doses) and evaluated the background factors associated with the titer. We enrolled 230
 25 participants (101 men and 129 women). Their average age was 71.9 (SD 12.5) years,
 26 and median was 72 years. The anti-SARS-CoV-2S antibody titer varied from 0.55 U/mL
 27 to 4920 U/mL. We found that the value of the titer varied widely. The value of the titer
 28 was negatively associated with age, alcohol consumption, time elapsed from second
 29 vaccine dose, and use of immunosuppressive medication. The result that the titer was
 30 negatively associated with aging suggests that the timing of additional shot should be
 31 carefully determined especially among elderly population.

32

33 **Introduction**

34 Even though the BNT162b2 mRNA vaccine against COVID-19 has shown to be
 35 effective in controlling the COVID-19 pandemic in many countries[1][2], cases of
 36 breakthrough infection, i.e., COVID-19 infection despite complete vaccination have

37 been reported[3]. Further, while the booster is also currently available in several
38 countries, the optimal timing for its administration has not yet been clearly established.
39 It is important for the elderly, who tend to have serious COVID-19 infection and high
40 mortality rates[4], to maintain sufficient immunity.

41 The presence of the anti-SARS-CoV-2S antibody has been reported to be
42 related to reduced risk of the infection[5]. However, previous studies on titer mainly
43 targeted health-care workers and those who targeted elderly population is scarce. We
44 reviewed the medical charts of predominantly elderly population to obtain the data on
45 serum anti-SARS-CoV-2S antibody titer after complete vaccination with the BNT162b2
46 mRNA vaccine (two doses) and evaluated the background factors associated with the
47 titer.

48

49 **Methods**

50 The participants of this study had no clinical history of COVID-19, had received both
51 doses of the BNT162b2 mRNA vaccine in 2021, and were tested for serum
52 anti-SARS-CoV-2S antibody titer at Nagase Clinic in Tokyo, Japan. All participant data
53 were obtained from their medical charts including age, sex, history of drinking and
54 smoking, time elapsed from the second vaccine dose to blood sampling, whether

55 prescribed immunosuppressive medication, as well as the titer. The titer measurement
56 was performed on clinical purpose to confirm they had sufficient immunity against
57 SARS-CoV-2S between August–October 2021. It was outsourced to LSI Medience
58 Corporation, a company that provides a clinical laboratory service, and they used the
59 Elecsys Anti-SARS-CoV-2S RUO (Roche Diagnostics). Titer values ≥ 0.8 U/mL were
60 defined as positive.

61 This study was approved by the ethics committee of Ibaraki University (N.
62 210300). Informed consent was obtained from all the participants in this study.

63 We used stepwise multivariate linear regression to identify factors associated
64 with serum anti-SARS-CoV-2S antibody titer. Nominal data were converted to dummy
65 variables and the titer value was used as the explanatory variable. Response variables
66 were sex (female: 0, male: 1), age, time elapsed after second immunization (days),
67 alcohol consumption (no: 0, occasionally: 1, almost every day: 2), smoking habit
68 (non-smoke: 0, smoke: 1), and use of immunosuppressive medication (no: 0, yes: 1).
69 Statistical Package for Social Sciences (SPSS, ver. 28) was used for statistical analyses;
70 $P < 0.05$ was considered statistically significant.

71

72 **Results and discussion**

73 We enrolled 230 participants (101 men and 129 women), and all participants were
74 Japanese. Participant age ranged from 35 to 101 years, and 82.2% were 60 years or
75 older. Average age was 71.9 ± 12.5 years (mean $\pm$ SD), while mode was 81 years,
76 median was 72 years, and first and third quartiles (Q1–Q3) were 64 and 81 years,
77 respectively. Next, while 18 participants consumed alcohol almost every day, 72 from
78 time to time and 140 did not, 18 participants smoked and 10 required
79 immunosuppressive medication for rheumatoid arthritis. The time from second dose of
80 vaccine to blood sampling ranged from 27 to 137 days (mean, 86.7 ± 23.0 days; median,
81 87 days; Q1–Q3, 72 and 104 days, respectively).

82 The anti-SARS-CoV-2S antibody titer varied from 0.55 U/mL to 4920 U/mL
83 and the distribution is depicted in Figure 1. The data showed a mode of 419.0 U/mL,
84 median of 382.5 U/mL, and Q1–Q3 values of 197.8 U/mL and 789.3 U/mL, respectively.
85 All but one of the participants had titer levels that were categorized as positive.

86

87 **Fig 1. The distribution of the anti-SARS-CoV-2S antibody titer.**

88 The distribution of the anti-SARS-CoV-2S antibody titer varied widely from 0.55 U/mL
89 to 4920 U/mL. The data showed a mode of 419.0 U/mL, median of 382.5 U/mL, and
90 Q1–Q3 values of 197.8 U/mL and 789.3 U/mL, respectively.

91

92 The results of multivariate linear regression analysis are summarized in Table 1

93 and the independent factors associated with titer levels were age, alcohol consumption,

94 time elapsed from second vaccine dose, and use of immunosuppressive medication.

95 **Table 1. Summary of multivariate analysis to evaluate the factors associated with**

96 **antibody titer.**

Variables	Standardized regression coefficient	95% confidence interval		P value	VIF
Age	-0.28	-19.89	-6.88	< 0.01	1.28
Alcohol	-0.23	-332.92	-101.74	< 0.01	1.05
Days from the second shot	-0.19	-8.46	-1.42	< 0.01	1.26
Immunosuppressant	-0.15	-797.42	-88.6	0,02	1.01
(Adjusted R2 = 0.19)					

97 We show that the anti-SARS-CoV-2S antibody titer varied widely even though all

98 participants had received both vaccine doses and that age, longer time from second

99 vaccine dose, alcohol consumption, and use of immunosuppressive medication were

100 related to lower titer.

101 Median titer values reported by previous studies that used identical

102 measurement methods are 2060.0 U/mL[6] and 764 U/mL[7], which are greater than our

103 result of 419.0 U/mL. This difference may be attributed to older participants in our
104 study compared to those in previous studies[6] [7] and to a comparatively longer
105 duration between sampling and second vaccination dose[6].

106 The association between aging and lower titer is consistent with results from
107 previous reports[6]–[9]. The association between alcohol consumption, time from the
108 second vaccine dose, and use of immunosuppressive medication with lower titer are
109 also consistent with the report by Kageyama et al[6].

110 One strength of our study is that we were able to analyze titer among the
111 elderly, and we believe that our study would provide information useful for optimal
112 scheduling of additional vaccinations. Our study also has a limitation. We excluded
113 participants who had a clinical history of COVID-19, but our study cohort could have
114 included some asymptomatic cases as we neither measured antibody titers before the
115 first vaccination dose nor performed PCR to rule out infection.

116

117 **Conclusion**

118 We found that the value of the titer varied widely. We also found that the value is
119 negatively associated with some factors including aging and time from the second
120 vaccine dose. As the elderly tend to have serious COVID-19 infection and high

121 mortality rates⁴, the timing of additional shot should be carefully determined.

122

123 **Acknowledgement**

124 We acknowledge the staff of Nagase Clinic for their co-operation.

125

126 **References**

127 1. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA et al. BNT162b2 mRNA

128 Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021;

129 384(15):1412-1423. doi: 10.1056/NEJMoa2101765.

130

131 2. Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in

132 real-world studies: a systematic review and meta-analysis. Infect Dis Poverty. 2021;

133 10(1): 132. doi: 10.1186/s40249-021-00915-3.

134

135 3. Christensen PA, Olsen RJ, Long SW, Subedi S, Davis JJ, Hodjat P et al. Delta

136 variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19

137 cases in Houston, Texas. Am J Pathol. 2021; S0002-9440(21)00480-6.

138 doi: 10.1016/j.ajpath.2021.10.019.

139

140 4. Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz

141 G. Assessing the age specificity of infection fatality rates for COVID-19: systematic

142 review, meta-analysis, and public policy implications. *Eur J Epidemiol.* 2020;

143 35(12):1123-1138. doi: 10.1007/s10654-020-00698-1.

144

145 5. Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB et al.

146 Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. *N*

147 *Engl J Med.* 2021; 384(6):533-540. doi: 10.1056/NEJMoa2034545.

148

149 6. Kageyama T, Ikeda K, Tanaka S et al. Antibody responses to BNT162b2 mRNA

150 COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral

151 hospital in Japan. *Clin Microbiol Infect.* 2021; doi: 10.1016/j.cmi.2021.07.042.

152

153 7. Nomura Y, Sawahata M, Nakamura Y et al. Age and smoking predict antibody titers

154 at 3 months after the second dose of the BNT162b2 COVID-19 vaccine. *Vaccines*

155 (Basel). 2021; 9(9): 1042. doi: 10.3390/vaccines9091042.

156

157 8. Müller L, Andrée M, Moskorz W, Drexler I, Walotka L, Grothmann R et al.

158 Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19

159 vaccination. Clin Infect Dis. 2021; 73(11):2065-2072. doi: 10.1093/cid/ciab381.

160

161 9. Terpos E, Trougakos IP, Apostolakou F et al. Age-dependent and gender-dependent

162 antibody responses against SARS-CoV-2 in health workers and octogenarians after

163 vaccination with the BNT162b2 mRNA vaccine. Am J Hematol. 2021; 96(7):

164 E257-E259. doi: 10.1002/ajh.26185.

165

166

167